Release date: 26 June 2015
Promoter – Financial Intermediary
UCB SALocation
Description
Financing of UCB New Medicines activities in the fields of neuroscience (Braine-l'Alleud, Belgium) and immunology (Slough, UK) over the period 2015-2017
Objectives
The project concerns the discovery research, non-clinical developments and early clinical developments, i.e. finding and confirming candidates and progressing them through proof of concept stage in the areas of neurology and immunology.
Comments
Professional, Scientific and Technical Activities
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 150 million
Total cost (Approximate amount)
EUR 426 million
Environmental aspects
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if, after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.
Status
Signed - 15/12/2015
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).